CN104922172A - Application and extraction method of sargentgloryvine stem extract - Google Patents
Application and extraction method of sargentgloryvine stem extract Download PDFInfo
- Publication number
- CN104922172A CN104922172A CN201510305581.4A CN201510305581A CN104922172A CN 104922172 A CN104922172 A CN 104922172A CN 201510305581 A CN201510305581 A CN 201510305581A CN 104922172 A CN104922172 A CN 104922172A
- Authority
- CN
- China
- Prior art keywords
- extract
- caulis sargentodoxae
- group
- sargentgloryvine stem
- mgl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a sargentgloryvine stem extract capable of inhibiting bone absorption and promoting bone formation and an extraction method of the sargentgloryvine stem extract, and belongs to the fields of extraction and application of Chinese traditional medicine. The extraction method comprises the following steps: conducting reflux extraction on dry sargentgloryvine stem with ethyl alcohol, combining extracting solutions, and carrying out vacuum concentration and freeze drying to obtain an alcohol extract; or boiling out the dry sargentgloryvine stem with water, and carrying out filtering, extracting solution combination, vacuum concentration and freeze drying to obtain water decoction. The sargentgloryvine stem extract is prepared from traditional Chinese medicine, is remarkable in bone absorption inhabitation and bone formation promotion, has less side effects, and is safe to use, simple in extraction method, and easy to develop.
Description
Technical field
The present invention relates to Chinese medicine extraction and application, particularly suppress bone resorption and the Caulis Sargentodoxae extract of promoting bone growing.
Background technology
Osteoporosis is one of principal disease of harm humans health, finds the key subjects that effective osteosporosis resistant medicament has become current field of medicaments.So that its aboundresources, low price, toxic and side effects be little etc., many advantages has larger Potential & advantage to Chinese medicine in protect against osteoporosis.Along with the development of the modernization of Chinese medicine, treatment by Chinese herbs osteoporosis is expected to be deep into cellular and molecular level and therefrom filters out Chinese medicine monomer or the compound recipe component of efficient, stable, low toxicity, gives full play to the advantage of Chinese herb prevention osteoporosis.
Osteoclast is responsible for bone resorption, and osteoblast is responsible for bone formation, and when this, two kinds of functioning cell effects are unbalance will cause osteoporosis.According to the effect in osseous tissue of osteoclast, osteoblast, drugs on the impact of its differentiation and maturation and function, find suppress bone resorption, the compound of promoting bone growing is one of important means of exploitation treatment medicine for treating osteoporosis.
Caulis Sargentodoxae is plants of Lardizabalaceae Caulis Sargentodoxae
sargentodoxa Cuneata(Oliv.) the dry rattan of Rehd. et Wils..Bitter in the mouth, property is put down, and returns large intestine, Liver Channel.There is heat-clearing and toxic substances removing, invigorate blood circulation, the effect of wind-expelling pain-stopping.For treating swelling and pain by traumatic injury, rheumatic arthralgia etc.Chinese herb prevention osteoporosis is many starts with from liver and kidney tonifying, bone and muscle strengthening, benefiting QI and nourishing blood, blood circulation promoting and blood stasis dispelling.
Summary of the invention
The object of this invention is to provide to have and suppress bone resorption and the Caulis Sargentodoxae extract of promoting bone growing effect.Caulis Sargentodoxae extract provided by the invention is Caulis Sargentodoxae ethanol extract and decocting thing.
The present invention is achieved in that
Caulis Sargentodoxae extract is for suppressing the application of bone resorption and promoting bone growing.
The extracting method of described Caulis Sargentodoxae extract, comprises the following steps: (1) gets dry Caulis Sargentodoxae, pulverizes for subsequent use; (2) the Caulis Sargentodoxae alcohol reflux will pulverized, filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains ethanol extract; The Caulis Sargentodoxae decocting maybe will pulverized, filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains decocting thing.
Described ethanol is the alcoholic solution of 60-80%.
Described reflux, extract, number of times is 2-4 time, and the time is 1-4h.
Described decocting number of times is 2-4 time, and the time is 1-3h.
Take Caulis Sargentodoxae as natural pharmaceutical resources, by multi-solvents extraction method and separation method, and the extract that the obtains activity experiment to bone resorption and osteoplastic effect of combining closely in extracting and developing process, finally obtain that there is the Caulis Sargentodoxae extract significantly suppressing bone resorption and promoting bone growing effect.
Beneficial effect of the present invention: the ground such as Caulis Sargentodoxae main product Hubei China, Sichuan, Jiangxi, Henan, Jiangsu, aboundresources.Caulis Sargentodoxae contains the Multiple components such as tannin class, glucosides class, ring Polyphenols, triterpene saponin, lignin, flavonoid, has radioprotective, anoxia enduring, antibacterial, calm, antiinflammatory, antiviral, the pharmacological action such as anticancer.Chinese herb prevention osteoporosis is many starts with from liver and kidney tonifying, bone and muscle strengthening, benefiting QI and nourishing blood, blood circulation promoting and blood stasis dispelling, and as the strong hematonic of one, normal and other drug matching of Caulis Sargentodoxae uses treats rheumatism bones and muscles pain, traumatic injury etc.Still there is no effective ingredient and the mechanism of action in clear and definite Caulis Sargentodoxae with osteoporosis disease at present.
Suppress bone resorption and promoting bone growing to be the effective ways for the treatment of osteoporosis, the present invention is by alcohol extraction and decocting, and the Caulis Sargentodoxae extract of be inhibited bone resorption promoting bone growing, extracting method is simple, and effect significantly, is easy to exploitation.
Accompanying drawing explanation
Fig. 1 be the Caulis Sargentodoxae extract of embodiment 3 on the impact of TRAP enzyme activity, with blank group ratio, *
p<0.05, * *
p<0.01;
Fig. 2 be the Caulis Sargentodoxae extract of embodiment 3 on the impact of TRAP staining positive cells quantity, with blank group ratio, *
p<0.05, * *
p<0.01;
Fig. 3 is each group of osteoclast TRAP dyeing (100 ×) of embodiment 3;
Fig. 4 be the Caulis Sargentodoxae extract of embodiment 3 on the impact of resorption pit of osteoclast in vitro scalar product, with blank group ratio, *
p<0.05, * *
p<0.01;
Fig. 5 be the Caulis Sargentodoxae extract of embodiment 3 on the impact of resorption pit of osteoclast in vitro area, with blank group ratio, *
p<0.05, * *
p<0.01;
Fig. 6 is each group of resorption pit of osteoclast in vitro Toluidine blue staining (100 ×) of embodiment 3.
Detailed description of the invention
1 material and instrument
1.1 material
Caulis Sargentodoxae, purchased from Siping City BAICAO hall prepared slices of Chinese crude drugs company limited, lot number: 20130401.
1.2 instrument
RE-52AA type Rotary Evaporators, purchased from Shanghai Yarong Biochemical Instrument Plant; LGJ-12 type freezer dryer, purchased from Beijing development in science and technology company limited of Song Yuan Huaxing.
The preparation of 2 ethanol extract
Get Caulis Sargentodoxae, pulverize, with alcohol reflux, filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains ethanol extract.
The preparation of 3 decocting things
Get Caulis Sargentodoxae, pulverize, with decocting, filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains decocting thing.
Preferably, the ethanol described in step 2 is the alcoholic solution of 60-80%.
Preferably, the reflux, extract, number of times described in step 2 is 2-4 time, and the time is 1-4h.
Preferably, the decocting number of times described in step 3 is 2-4 time, and the time is 1-3h.
Embodiments of the invention 1: get Caulis Sargentodoxae 100 g, by 75% ethanol 1000 mL reflux, extract, 3 times, the time is respectively 3 h, 2 h, 1 h, and filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains ethanol extract.Get ethanol extract 200 mg molten in 1mL DMSO, make 200 mgmL
-1storing solution, gradient dilution is to 20 mgmL
-1with 2 mgmL
-1for subsequent use.
Embodiments of the invention 2: get Caulis Sargentodoxae 100 g, decoct 3 times with water 1000 mL, and the time is respectively 2.5 h, 2 h, 1.5 h, and filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains decocting thing.It is molten in 1mL DMSO that thing 200 mg is decocted in water intaking, makes 200 mgmL
-1storing solution, gradient dilution is to 20 mgmL
-1with 2 mgmL
-1for subsequent use.
Embodiments of the invention 3: Caulis Sargentodoxae extract is on the impact of differentiation of osteoclast and bone resorption function.
(1) separation of medullary cell and inducing culture: the neck that broken by the newborn rabbit in birth 48 h is put to death, 75% alcohol-pickled sterilization, hind leg femur and tibia is peeled off in aseptic operating platform, be placed in cold PBS, after divesting soft tissue with sterile gauze, backbone is placed in containing the full culture medium of α-MEM (containing 10% hyclone, penicillin 100 IU/mL, streptomycin 100 mg/mL) in sterile petri dish, then with the surgical scissors of sterilizing, backbone is longitudinally cut off, gently scrape the cell in bone until bone inner surface bleaches, shred and key merging shake about 1 min based in tool plug glass tubing through whirlpool containing cell culture, required cell suspension is made into after crossing 200 order cell sieves, according to 1 ~ 2 × 10
6the density in individual/hole is inoculated in 24 well culture plates (0.5 mL/ hole), is placed in 5% CO
2, 37 DEG C, cultivate under saturated humidity condition.About 24 h PBS washes non-attached cell off, adds containing 10
-8molL
-11 α, 25-(OH)
2vitD
3culture medium induce, and count first day, then within every 3 days, change once containing 10
-8molL
-11 α, 25-(OH)
2vitD
3full culture medium.
(2) Caulis Sargentodoxae extract is on the impact of medullary cell to differentiation of osteoclast:
1. TRAP vitality test: separation and Culture cell according to the method described above, about 24 h change containing 10
-8molL
-11 α, 25-(OH)
2vitD
3with the full culture medium of each dose drug, then within every 3 days, change once above-mentioned culture medium.Be divided into blank group (DMSO, 1 μ LmL
-1), ethanol extract low dose group (EL, 2 mgL
-1), dosage group (EM, 20 mgL in ethanol extract
-1), ethanol extract high dose group (EH, 200 mgL
-1), water extract low dose group (WL, 2 mgL
-1), dosage group (WM, 20 mgL in water extract
-1), water extract high dose group (WH, 200 mgL
-1) administration, often group establishes 4 multiple holes, and pharmaceutical intervention carried out TRAP enzyme activity determination by the 8th day, first used 0.2% TritonX-100 cracking, then carry out according to Tartrate resistant acid phosphatase (StrACP) testing cassete (Nanjing is built up) description, detect in microplate reader 530 nm place light absorption values (
a), record data, are converted into King unit (U/L) according to the computing formula in description.
As shown in Figure 1, each group TRAP enzyme activity value is all less than blank group to result, and compared with blank group, dosage group (20 mgL in Caulis Sargentodoxae ethanol extract and water extract
-1) have significant difference (
p<0.05); Caulis Sargentodoxae ethanol extract and water extract high dose group (200 mgL
-1) group have pole significant difference (
p<0.01), 20 ~ 200 mgL are shown
-1caulis Sargentodoxae extract energy significance suppress osteoclast Tartrate resistant acid phosphatase vigor.
2. TRAP dyeing: after acid spends the night through cleaning, bubble by 1.0cm × 1.0cm slide, distilled water rinses, gauze is cleaned, and after autoclaving, puts into 24 aseptic well culture plates in superclean bench, one, every hole, it is for subsequent use to add appropriate PBS submergence.Isolated cell according to the method described above, sops up the PBS in 24 well culture plates, inoculating cell.About 24 h change containing 10
-8molL
-11 α, 25-(OH)
2vitD
3with the full culture medium of each dose drug, then within every 3 days, change once above-mentioned culture medium.Be divided into blank group (DMSO, 1
mL
-1), ethanol extract low dose group (EL, 2 mgL
-1), dosage group (EM, 20 mgL in ethanol extract
-1), ethanol extract high dose group (EH, 200 mgL
-1), water extract low dose group (WL, 2 mgL
-1), dosage group (WM, 20 mgL in water extract
-1), water extract high dose group (WH, 200 mgL
-1) administration, often group establishes 4 multiple holes, pharmaceutical intervention carried out TRAP dyeing by the 8th day, method is undertaken by tartaric-resistant test kit (Sigma) description, transparent through dimethylbenzene after dyeing, neutral gum mounting, in basis of microscopic observation, add up the positive cell number on whole slide.
Result as shown in Figures 2 and 3, the basic, normal, high dosage group of Caulis Sargentodoxae ethanol extract and water extract all can significantly suppress TRAP staining positive cells number (
p<0.01).
(3) Caulis Sargentodoxae extract is on the impact of osteoclastic bone resorption function: get bone abrasive disc, after being trimmed to 0.6 cm × 0.6 cm size, by PBS ultrasonic waves for cleaning three times, 75% soak with ethanol 2 more than h, ultra violet lamp in superclean bench, after each 1h in every face, puts into aseptic 24 well culture plates, one, every hole also adds appropriate PBS submergence, puts CO
2incubator 2 more than h, for subsequent use.Isolated cell according to the method described above, after sopping up the PBS in 24 well culture plates, inoculating cell.About 24 h change containing 10
-8molL
-11 α, 25-(OH)
2vitD
3with the full culture medium of each dose drug, then within every 3 days, change once above-mentioned culture medium.Be divided into blank group (DMSO, 1
mL
-1), ethanol extract low dose group (EL, 2 mgL
-1), dosage group (EM, 20 mgL in ethanol extract
-1), ethanol extract high dose group (EH, 200 mgL
-1), water extract low dose group (WL, 2 mgL
-1), dosage group (WM, 20 mgL in water extract
-1), water extract high dose group (WH, 200 mgL
-1) administration, often group establishes 3 multiple holes, and pharmaceutical intervention carried out bone abrasive disc Bone resoiption pit Toluidine blue staining by the 8th day, and take out osteocomma, PBS fine laundering 2 times, 10% formaldehyde fixes 8 min, then uses 0.25 molL
-1ammonia ultrasonic cleaning 3 times, each 5 min, graded ethanol dewaters, 1% toluidine blue dye liquor room temperature dyeing 3 ~ 4 min, naturally dry in microscopic examination after distilled water fine laundering, then use quantity and the area of the Bone resoiption pit of Image Pro Plus 6.0 software statistics whole bone abrasive disc.
Result as shown in Fig. 4, Fig. 5 and Fig. 6, Caulis Sargentodoxae ethanol extract and water extract each dosage group resorption pit of osteoclast in vitro quantity and be all less than blank group, and have compared with blank group pole significant difference (
p<0.01); Caulis Sargentodoxae ethanol extract and water extract each dosage resorption pit of osteoclast in vitro area all significance be less than blank group (
p<0.05), show that Caulis Sargentodoxae energy significance suppresses the bone resorption function of osteoclast.
Embodiments of the invention 4: Caulis Sargentodoxae extract is on the impact of osteoblastic proliferation and active function.
(1) Caulis Sargentodoxae extract is on the impact of osteoblastic proliferation: will be in the MC3T3-E1Subclone l4 cell suspension of exponential phase with every hole 5 × 10
3individually be seeded in 96 orifice plates, about 24 h change the full culture medium containing each dose drug.Be divided into blank group (DMSO, 1
mL
-1), ethanol extract low dose group (EL, 2 mgL
-1), dosage group (EM, 20 mgL in ethanol extract
-1), ethanol extract high dose group (EH, 200 mgL
-1), water extract low dose group (WL, 2 mgL
-1), dosage group (WM, 20 mgL in water extract
-1), water extract high dose group (WH, 200 mgL
-1) administration, and set up complete medium matched group, often group establishes 6 multiple holes, puts 37 DEG C, 5% CO
2cultivate in incubator, after pharmaceutical intervention 48 h, every hole adds 5 mg/mL MTT solution 20
, stop after continuing cultivation 4 h.Suction adds 150 after abandoning each culture hole supernatant respectively
dMSO, microwell plate oscillator vibrates 10 min, makes crystal fully dissolve, and microplate reader is colorimetric under 490 nm wavelength, record absorbance (
a), the relative appreciation rate of cell (%)=(
aexperimental group-
ablank)/(
ablank-
acomplete medium contrasts) × 100%.
Result is as shown in table 1, and low, the middle dosage group appreciation rate of Caulis Sargentodoxae ethanol extract and water extract is on the occasion of showing its propagation that can promote MC3T3-E1Subclone l4 cell, wherein dosage group and low, the middle dosage group of water extract in ethanol extract
avalue have compared with blank group significant difference (
p<0.05); Caulis Sargentodoxae ethanol extract and water extract high dose group appreciation rate are that negative value shows to which inhibits osteoblastic propagation.
table 1 Caulis Sargentodoxae extract on the impact of MC3T3-E1Subclone l4 cell proliferation ( ± s,
n=6
)
| Group | Drug level | AValue | Appreciation rate (%) |
| Blank | - | 0.328±0.009 | - |
| Full culture medium contrast | - | 0.050±0.012 | - |
| EL | 2 mg·L -1 | 0.344±0.017 * | 5.75 |
| EM | 20 mg·L -1 | 0.370±0.015 ** | 15.23 |
| EH | 200 mg·L -1 | 0.144±0.007 ** | -66.31 |
| WL | 2 mg·L -1 | 0.334±0.012 | 2.10 |
| WM | 20 mg·L -1 | 0.344±0.011 * | 5.82 |
| WH | 200 mg·L -1 | 0.264±0.023 ** | -23.20 |
With blank group ratio,
* p<0.05,
* p<0.01
(2) Caulis Sargentodoxae extract is on the impact of osteoblast alkaline phosphatase activity: by MC3T3-E1Subclone l4 cell with 1 × l0
4the density in/hole is inoculated into 96 well culture plates, puts 37 DEG C, 5%CO
2cultivate in incubator.About 24 h change containing L-AA (50
mL
-1), sodium β-glycerophosphate (10 mmolmL
-1), dexamethasone (10
-8molmL
-1) and the full culture medium of each dose drug.Be divided into blank group (DMSO, 1
mL
-1), ethanol extract low dose group (EL, 2 mgL
-1), dosage group (EM, 20 mgL in ethanol extract
-1), ethanol extract high dose group (EH, 200 mgL
-1), water extract low dose group (WL, 2 mgL
-1), dosage group (WM, 20 mgL in water extract
-1), water extract high dose group (WH, 200 mgL
-1) administration, often group establishes 4 multiple holes.After pharmaceutical intervention 72 h, abandon culture fluid, with PBS buffer fine laundering 2 times, every hole adds cell pyrolysis liquid l00
(1%TritonX-100) 4 DEG C of cracking 30 min, operate according to the operation table of Alkaline Phosphatase Kit, are converted into King unit according to the computing formula in description.King unit defines: it is a unit of activity that every gram of histone produces 1mg phenol at 37 DEG C with substrate effect 15 min.Measure its protein concentration by BCA method simultaneously.Computing formula on by specification calculates enzyme activity.
Result is as shown in table 2, and Caulis Sargentodoxae ethanol extract and water extract each dosage group alkaline phosphatase activity value are all greater than blank group, show Caulis Sargentodoxae to alkali phosphatase (ALP) vigor in MC3T3-E1Subclone l4 cell have significance facilitation (
p<0.01).
table 2 Caulis Sargentodoxae extract on the impact of MC3T3-E1Subclonel4 Cellular alkaline phosphatase vigor ( ± s,
n=4
)
| Group | Drug level | Alkaline phosphatase activity (King unit/ Albumen) |
| Blank | - | 1.23±0.82 |
| EL | 2 mg·L -1 | 9.70±1.20 ** |
| EM | 20 mg·L -1 | 27.33±1.60 ** |
| EH | 200 mg·L -1 | 11.21±2.15 ** |
| WL | 2 mg·L -1 | 9.34±1.47 ** |
| WM | 20 mg·L -1 | 15.06±2.80 ** |
| WH | 200 mg·L -1 | 8.72±0.98 ** |
With blank group ratio,
* p<0.05,
* p<0.01.
Claims (5)
1. Caulis Sargentodoxae extract is for suppressing the application of bone resorption and promoting bone growing.
2. the extracting method of Caulis Sargentodoxae extract as claimed in claim 1, is characterized in that, comprise the following steps: (1) gets dry Caulis Sargentodoxae, pulverizes for subsequent use; (2) the Caulis Sargentodoxae alcohol reflux will pulverized, filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains ethanol extract; The Caulis Sargentodoxae decocting maybe will pulverized, filter, merge extractive liquid, after concentrating under reduced pressure, lyophilization, obtains decocting thing.
3. according to the extracting method of claim 2 Caulis Sargentodoxae extract, it is characterized in that, described ethanol is the alcoholic solution of 60-80%.
4. according to the extracting method of claim 2 Caulis Sargentodoxae extract, it is characterized in that, described reflux, extract, number of times is 2-4 time, and the time is 1-4h.
5. according to the extracting method of claim 2 Caulis Sargentodoxae extract, it is characterized in that, described decocting number of times is 2-4 time, and the time is 1-3h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510305581.4A CN104922172A (en) | 2015-06-08 | 2015-06-08 | Application and extraction method of sargentgloryvine stem extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510305581.4A CN104922172A (en) | 2015-06-08 | 2015-06-08 | Application and extraction method of sargentgloryvine stem extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104922172A true CN104922172A (en) | 2015-09-23 |
Family
ID=54109827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510305581.4A Pending CN104922172A (en) | 2015-06-08 | 2015-06-08 | Application and extraction method of sargentgloryvine stem extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104922172A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697822A (en) * | 2012-06-04 | 2012-10-03 | 江苏大学 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
-
2015
- 2015-06-08 CN CN201510305581.4A patent/CN104922172A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697822A (en) * | 2012-06-04 | 2012-10-03 | 江苏大学 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
Non-Patent Citations (5)
| Title |
|---|
| 付钰等: "中药大血藤对佐剂性关节炎大鼠滑膜细胞MMP-2 、MMP-9 的影响", 《贵州医药》 * |
| 唐鹏等: "基质金属蛋白酶对原发性骨质疏松及骨质疏松骨折发病机制的影响", 《中华骨质疏松和骨矿盐疾病杂志》 * |
| 王伟等: "比色法测定大血藤中总黄酮含量及其清除DPPH自由基研究", 《江苏农业科学》 * |
| 蔡辉等: "单味活血化瘀中药治疗骨质疏松症的实验研究进展", 《中医药导报》 * |
| 马瑞丽等: "大血藤的化学成分及药理作用研究进展", 《中国野生植物资源》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1383381A (en) | Therpauetic agent of osteoporisis comprising active ingredient of quercetin derivatives | |
| CN103622980A (en) | Application of cistanche phenylethanoid glycoside compound to preparation of drugs for treating osteoporosis and drug composition containing cistanche phenylethanoid glycoside compound | |
| CN101664522A (en) | Chinese medicine composition preventing and curing varicella and preparation method thereof | |
| CN113616747A (en) | Traditional Chinese medicine composition for rehabilitation of infectious diseases and application thereof | |
| CN107375474B (en) | Vitiligo vitamine compound and preparation method thereof | |
| EP1862171B1 (en) | A medicine composition for treating muscular atrophy and myasthenia gravis and method of preparing the same | |
| CN101711796B (en) | Application of scullcapflavone in preparing medicament for treating enterovirus infection | |
| CN111991484A (en) | A pharmaceutical composition for treating respiratory diseases in winter | |
| CN115212243A (en) | Application of epimedium extract | |
| CN1330330C (en) | Antivirus medicinal composition, preparation method and use | |
| CN100586454C (en) | Chinese medicine composition for birds, preparing method and application of the same | |
| CN104474219A (en) | Drug for treating trionyx sinensis saprolegniasis caused by fungi | |
| CN108114010A (en) | Purposes of the pill of Eight Treasures in the drug for preparing prevention early liver cancer postoperative recurrence | |
| CN104906162A (en) | Preparing method and application of rhizoma atractylodis volatile oil | |
| CN113975314B (en) | Application of oil of Liaopo mountain Baicao in preparing medicine for inhibiting infection of coronavirus OC43 and SARS-Cov-2 in vitro | |
| CN102283838A (en) | Application of ethoxysanguinarine to pharmacy | |
| CN102813713B (en) | Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition | |
| CN104922172A (en) | Application and extraction method of sargentgloryvine stem extract | |
| CN104922268B (en) | A kind of method that active material is extracted from natural plants | |
| CN104546822A (en) | Medical application of anhydroicaritin | |
| CN109395015B (en) | Application of rheumatism and pain relieving traditional Chinese medicine composition in preparation of anti-angiogenesis medicine | |
| KR20160089892A (en) | Composition for the prevention and treatment of antiviral comprising extracts of crude drug complex | |
| CN101982188B (en) | Application of Tangut dragonhead in preparation of drugs for treating livestock and poultry viral infectious diseases | |
| CN111643612A (en) | Traditional Chinese medicine composition for preventing and treating new coronavirus pneumonia and preparation method and application thereof | |
| CN101810598B (en) | Medicinal composition for curing hepatitis C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150923 |
|
| RJ01 | Rejection of invention patent application after publication |